Background {#Sec1}
==========

Rectal cancer (RC) is one of the most common malignancies in the USA, and the incidence of RC in Asian countries is increasing rapidly and has been considered to be similar to that of the Western countries \[[@CR1]\]. Preoperative radiotherapy (Pre-RT) has become part of standard practice offered to improve treatment outcomes in patients with RC because of the oncologic benefit of reduced local recurrence rate \[[@CR2]\]. But till now, there is still lack of effective means for accurate prognostic evaluation on the survival.

It is widely thought that lymph node (LN) metastasis indicates worse tumor response grade and poorer survival. According to the guidelines for RC from the National Comprehensive Cancer Network, a minimum of twelve lymph nodes must be retrieved and examined for accurate staging and the number of metastatic LNs was validated as an independent prognostic factors \[[@CR3]\]. While the node-positive patients with RC are heterogeneous and the prognosis of these patients cannot be stratified by the node-stage only \[[@CR3], [@CR4]\]. Therefore, the concept of negative lymph node (NLN) counts has attracted attention recently as a prognostic indicator in various cancers, including breast \[[@CR5]\], cervical \[[@CR6]\], and esophagus \[[@CR7]\]. It has been reported that the number of NLNs was an independent prognostic factor for patients with colon cancer \[[@CR8]\]. However, Pre-RT can yield tumor downstaging, reduce the burden of residual microscopic disease at surgery and reduce the number of LNs retrieved in operation \[[@CR9]\]. With the decreased LNs retrieval, the prognostic value of the LN count might also diminish \[[@CR10]\]. It has been reported that increased number of NLNs is associated with improved survival in pathological IIIB and IIIC RC treated with Pre-RT \[[@CR7]\]. While it is still unclear whether NLN still has prognostic value count on survival of all patients with RC, including stage I and II, who received Pre-RT. The purpose of this study was to assess the association between NLN count and survival of patients with RC of all stages who received Pre-RT. In order to get convincing results in a larger series patients, we used the SEER (Surveillance, Epidemiology and End Results)-registered database to analyze this association, and determine the optimal cutoff value of NLN count.

Methods {#Sec2}
=======

Study population and data extracted {#Sec3}
-----------------------------------

The SEER (Surveillance, Epidemiology, and End Results Program) database and SEER-stat software (SEER∗Stat 8.3.2) were used to identify patients whose pathological diagnosis as RC between 2004 and 2010. Only patients who underwent Pre-RT and surgical treatment with age of diagnosis more than 18 years were included. Histological type were limited to adenocarcinoma (8140/3), carcinoma (8010/3; 8020/3; 8021/3 and 8145/3) and signet ring cell carcinoma (8490/3). Patients were excluded if they had only local excision following Pre-RT, multiple primary malignant neoplasms, incomplete TNM staging, with distant metastasis (M1), no evaluation on LNs, died within 30 days after surgery or information on CSS and survival months unavailable.

Year of diagnosis, age, sex, race, grade, histologic type, ypT stage, number of LNs examined, number of positive LNs and CSS were assessed. TNM classification was restaged according to the criteria described in the AJCC Cancer Staging Manual (7th edition, 2010).

Statistical analysis {#Sec4}
--------------------

The NLNs cutoff points were determined using the X-tile program, which identified the cutoff value with the minimum *P* values from log-rank χ2 statistics for the categorical NLNs in terms of CSS. Baseline characteristics were compared using the X2 test for nominal variables. Survival curves were generated using Kaplan-Meier analyses, and the differences between the curves were analyzed by log-rank test. Cox regression models were built for analysis of risk factors for survival outcomes. Statistical analyses were performed using the statistical software package SPSS for Windows, version 19.0 (SPSS Inc., Chicago, IL). All *P* values were two-sided. *P* \< 0.05 was considered statistically significant.

Results {#Sec5}
=======

Patient characteristics from SEER database {#Sec6}
------------------------------------------

In SEER database, we selected a total of 6068 patients with RC who received Pre-RT, including 3881 male and 2187 female from 2004 to 2010. The median age of patients was 59 years. There were 4042 patients with stage ypN0, 1352 with stage ypN1 and 674 with stage ypN2.

The optimal cutoff value for NLN count calculated by X-tile {#Sec7}
-----------------------------------------------------------

To assess the influence of different NLN count on CSS, we analyzed the individual result using different NLN count ranging from 0 to 23. The 5-year CSS was calculated for patients with N (NLNs number) or more nodes and less than N nodes. As shown in Table [1](#Tab1){ref-type="table"}, NLN count in patients with RC who received Pre-RT was a prognosis factor for number ranging from 0 to 23. With the NLN count increased from 0 to 23, the 5-year CSS rate increased from 51.8 to 88.8% (Table [1](#Tab1){ref-type="table"}). Next X-tile plots were constructed and the maximum χ2 log-rank value of 78.060 (the number as 9, Fig. [1](#Fig1){ref-type="fig"}, *P* \< 0.001) was produced, applying 9 as the optimal cutoff value to divide the cohort into high and low risk subsets in terms of CSS. There was a significant improvement in 5-year CSS between two subsets (74.3% v.s. 82.8%, Table [1](#Tab1){ref-type="table"}). As shown in Table [2](#Tab2){ref-type="table"}, the year of diagnosis, sex, age and the average number of LNs dissected were significantly different between patients with NLN ≤ 9 or \>9 (*P* \< 0.05).Table 1Univariate analysis of the influence of different NLN count on CSS in RC patients who received Pre-RTLNsNo.5-year CCSχ2*P* valueLNsNo.5-year CCSχ2*P* value≤07251.8%41.7450.000≤12368576.5%42.7630.000\>0599679.5%\>12238383.3%≤123063.5%50.1000.000≤13402276.9%38.7470.000\>1583879.7%\>13204683.6%≤244468.2%44.1320.000≤14432077.3%33.9390.000\>2562480.0%\>14174883.7%≤372069.0%54.4960.000≤15458577.3%36.4350.000\>3534880.5%\>15148384.8%≤4101570.0%67.3750.000≤16482277.6%33.0370.000\>4505381.0%\>16124685.3%≤5131471.8%68.4320.000≤17501372.8%27.8270.000\>5475481.2%\>17105585.4%≤6162572.5%74.9790.000≤18517778.0%23.5460.000\>6444381.6%\>1889185.5%≤7197473.5%74.3020.000≤19530278.0%25.4480.000\>7409481.9%\>1976686.8%≤8228574.2%70.4050.000≤20542278.2%25.2570.000\>8378382.1%\>2064687.2%≤9261374.3%78.0600.000≤21552877.9%21.1200.000\>9345582.8%\>2154087.5%≤10297375.0%67.2360.000≤22560678.4%21.7300.000\>10309583.1%\>2246288.0%≤11332075.6%57.6630.000≤23567178.5%18.8720.000\>11274883.4%\>2339788.8% Fig. 1X-tile analysis of survival data from the SEER registry. X-tile analysis was performed using patient data, equally divided into training and validation sets, from the SEER registry. In X-tile plots of the training sets (**a**), the plots of matched validation sets are shown in the smaller inset. The optimal cut-point highlighted by the *black circle* (**a**) is shown on a histogram of the entire cohort (**b**), and a Kaplan-Meier plot (**c**). *P* values were determined using the cutoff point defined in the training set and applying it to the validation set. (The optimal cutoff value for NLN count is 9, χ2 = 78.060, *P* \< 0.001) Table 2Comparison of clinical characteristics of patients with NLN ≤ 9 or NLN \> 9CharacteristicTotalNLN ≤ 9NLN \> 9*P* value606826133455Follow upMedian (IQU)58 (42-81) monthsYear of diagnosis0.0002004--20073122155315692008--2010294610601886Sex0.007Male388116252256Female21879881199Age0.000\<60336813652003≥60270012481452Race0.593White492721372790Black511214297Others630262368Grade0.222Grade I/ II509821842914Grade III/ IV970429541Histologic type0.430Adenocarcinoma551723673150Mucinous adenocarcinoma490215275Signet ring cell carcinoma613130ypT stage3861891970.0621957425532243061820248634191792404LNs dissected12.796.9217.230.000

Impact of the NLN count on CSS in RC patients who received Pre-RT {#Sec8}
-----------------------------------------------------------------

According to univariate analysis, age (≥ 60), race (black persons), grade (III/IV), histologic type (signet ring cell carcinoma), ypT stage (ypT3 and ypT4) and NLNs (≤ 9) were associated with poor outcomes in patients with RC who received Pre-RT (*P* \< 0.001) (Table [3](#Tab3){ref-type="table"}). In multivariate Cox analysis, age, grade, histologic type, ypT stage and NLN counts were independently prognostic factors (*P* \< 0.001, Table [3](#Tab3){ref-type="table"}). NLN counts (\> 9) exhibited a favorable effect on survival (HR = 1.623, 95% CI 1.457 \~ 1.809, *P* \< 0.001, Table [3](#Tab3){ref-type="table"}).Table 3Univariate and multivariate survival analyses of RC patients who received Pre-RTCharacteristic5-year CCSUnivariate analysisMultivariate analysisχ2 test*P*HR(95%CI)*P*Year of diagnosis2.4120.120NI 2004--200778.4% 2008--201080.2%Sex1.6550.198NI Male29.5% Female78.4%Age21.8050.0000.000 \< 6081.3%Ref ≥ 6076.4%0.777 (0.697 \~ 0.866)0.000Race14.8730.0000.909 White79.5%Ref Black72.7%1.129 (0.937 \~ 1.364)0.202 Others81.8%1.585 (1.246 \~ 2.017)0.000Grade112.3630.0000.000 Grade I/ II81.5%Ref Grade III/ IV66.9%0.596 (0.523 \~ 0.680)0.000Histologic type81.1280.0000.000 Adenocarcinoma80.4%Ref Mucinous adenocarcinoma69.2%0.412 (0.308 \~ 0.635)0.000 Signet ring cell carcinoma32.5%0.601 (0.408 \~ 0.885)0.010ypT stage148.3230.0000.000 188.6%Ref 287.9%0.293 (0.212 \~ 0.405)0.000 377.9%0.303 (0.239 \~ 0.384)0.000 462.6%0.584 (0.494 \~ 0.692)0.000LNs2.2340.135NI ≤ 1278.5% \> 1279.8%NLN78.0600.0000.000 ≤ 974.3%Ref \> 982.8%1.623 (1.457 \~ 1.809)0.000

Impact of the NLN count on CSS in RC patients based on each pathological grade {#Sec9}
------------------------------------------------------------------------------

We then further analyzed of the effects of NLN on survival in each subgroup of stage yp I, yp II and yp III. As shown in Fig. [2](#Fig2){ref-type="fig"}, subgroup analysis showed that NLN was a prognosis factor for patients with RC who received Pre-RT in stage ypI (χ2 = 7.080; *P* = 0.008), ypII (χ2 = 20.806; *P* \< 0.001) and ypIII (χ2 = 33.138; *P* \< 0.001), respectively. Moreover, as shown in Tables [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}, the NLN count was also an independently prognostic factor in stage ypII (HR: 1.520, 95%CI: 1.170 \~ 1.975; *P* = 0.002) and ypIII (HR: 1.466, 95%CI: 1.264 \~ 1.700; *P* \< 0.001) after adjustment for potential confounders.Fig. 2Log-rank tests of CSS comparing patients with NLNs (\<9 VS ≥9) for (**a**) stage ypI: *P* = 0.008; (**b**) stage ypII: *P* \< 0.001; and (**c**) stage ypIII: *P* \<0.001 Table 4Univariate and multivariate survival analyses of stage ypI RC patients who received Pre-RTCharacteristic5-year CCSUnivariate analysisMultivariate analysisχ2 test*P*HR(95%CI)*P*Year of diagnosis6.3240.0120.035 2004--200787.9%Ref 2008--201092.2%1.609 (1.029 \~ 2.517)0.037Sex1.2380.266NI Male90.0% Female89.3%Age2.3590.125NI \< 6091.3% ≥ 6088.0%Race6.2220.0450.053 White88.9%Ref Black81.0%3.792 (1.201 \~ 11.968)0.023 Others98.9%4.392 (1.251 \~ 15.415)0.021Grade0.4830.487NI Grade I/ II90.0% Grade III/ IV85.1%Histologic type3.2180.200NI Adenocarcinoma89.8% Mucinous adenocarcinoma89.5% Signet ring cell carcinoma50.0%ypT stage0.0010.972NI 190.5% 289.4%LNs9.4010.0020.284 ≤ 1287.8%Ref \> 1293.4%1.702 (0.949 \~ 3.052)0.074NLN7.0800.0080.600 ≤ 987.6%Ref \> 991.6%1.128 (0.682 \~ 1.866)0.638 Table 5Univariate and multivariate survival analyses of stage ypII RC patients who received Pre-RTCharacteristic5-year CCSUnivariate analysisMultivariate analysisχ2 test*P*HR(95%CI)*P*Year of diagnosis0.2550.614NI 2004--200784.1% 2008--201084.7%Sex1.4140.234NI Male85.1% Female83.0%Age21.4350.0000.000 \< 6087.2%Ref ≥ 6081.1%0.677 (0.566 \~ 0.810)0.000Race1.8120.404NI White84.6% Black81.4% Others84.4%Grade24.5520.0000.000 Grade I/ II85.6%Ref Grade III/ IV76.2%0.599 (0.479 \~ 0.748)0.000Histologic type6.7050.0350.042 Adenocarcinoma85.0%Ref Mucinous adenocarcinoma75.9%0.786 (0.249 \~ 2.481)0.682 Signet ring cell carcinoma71.6%1.103 (0.339 \~ 3.590)0.871ypT stage21.3010.0000.000 385.4%Ref 473.2%0.591 (0.445 \~ 0.767)0.000LNs9.6480.0020.892 ≤ 1282.5%Ref \> 1286.7%0.983 (0.749 \~ 1.289)0.900NLN20.8060.0000.002 ≤ 980.9%Ref \> 986.5%1.520 (1.170 \~ 1.975)0.002 Table 6Univariate and multivariate survival analyses of stage ypIII RC patients who received Pre-RTCharacteristic5-year CCSUnivariate analysisMultivariate analysisχ2 test*P*HR(95%CI)*P*Year of diagnosis0.0380.846NI 2004--200765.6% 2008--201067.0%Sex0.0260.872NI Male65.9% Female66.2%Age17.2450.0000.000 \< 6069.3%Ref ≥ 6060.9%0.747 (0.654 \~ 0.866)0.000Race17.5350.0000.625 White66.8%Ref Black51.6%1.125 (0.880 \~ 1.436)0.347 Others71.3%1.767 (1.290 \~ 2.421)0.000Grade41.7220.0000.000 Grade I/ II69.5%Ref Grade III/ IV53.9%0.670 (0.566 \~ 0.794)0.000Histologic type24.6170.0000.037 Adenocarcinoma67.4%Ref Mucinous adenocarcinoma60.7%0.562 (0.378 \~ 0.836)0.004 Signet ring cell carcinoma41.8%0.588 (0.383 \~ 0.904)0.016ypT stage66.2410.0000.000 173.0%Ref 283.7%0.442 (0.242 \~ 0.810)0.008 365.1%0.276 (0.195 \~ 0.391)0.000 446.8%0.564 (0.451 \~ 0.704)0.000LNs1.9750.160NI ≤ 1264.9% \> 1267.0%NLN33.1380.0000.000 ≤ 960.5%Ref \> 971.4%1.466 (1.264 \~ 1.700)0.000

Discussion {#Sec10}
==========

LN metastasis is considered as one of the most significant prognostic factors in RC \[[@CR11]\]. The total number of LNs retrieved is fundamental in most pathological staging systems for RC. Inadequate LN evaluation is associated with worse outcomes in terms of tumor recurrence and patient survival \[[@CR12]\]. Thus, looking for effective means of assessment of LNs on survival can provide more accurate prognostic information.

According to the AJCC-7 RC staging system, a 12-node minimum is required for proper tumor stage and associated with a good survival outcome in patients treated with surgery \[[@CR3]\]. Yet, the number of positive LN is often affected by many facts such as neoadjuvant therapy, and the number of LN retrieved and inspected \[[@CR3]\]. Once the range of LN retrieved is not enough, the prediction of survival would be inaccurate. Therefore, the concept of NLN has been developed recently. NLN count has a unique advantage that it is little influenced by the number of LN retrieved \[[@CR13]\]. The more NLN count is, the better the survival would be. Li et al. \[[@CR12]\] reported that the optimal cutoff value of 10 was validated as an independent prognostic factor in stage ypIIIB and ypIIIC RC patients treated with Pre-RT. In this study, we found that the NLN count was an independent prognosis factor for all patients with RC who received Pre-RT. And we identified the optimal cutoff value for NLN count as 9. Obviously, NLN count is a good supplement for LN stage and TNM stage on evaluating the prognosis of patients with RC who received Pre-RT, respectively for patients with stage ypI, ypII and ypIII. Until now, there has been no report confirming the mechanism of NLNs influencing on the prognosis of RC. But it is suggested that lymphatic micrometastasis is a key etiology of recurrence and metastasis after resection of RC \[[@CR14]\]. LN micrometastasis, is common in nodes with the size ranging from 0.2 to 2.0 mm which determined to be negative by HE staining, but positive for cytokeratin (CK) by immunohistochemical staining \[[@CR15]\]. Because it is difficult to find lymphatic micrometastasis during operation, we can retrieve more NLNs to reduce the residual micrometastases, in order to improve the prognosis of RC.

The intended purpose of Pre-RT is tumor down-staging by decreasing the primary tumor bulk and reducing the burden of residual associated LN metastases at surgery, thus increasing the potential of margin-negative resections \[[@CR9]\]. It has been reported that Pre-RT may cause radiation-induced lymphocyte destruction and stromal fibrosis resulting in alterations of the morphology of the LNs, making LN detection during operation more difficult \[[@CR9]\]. Some researchers found that a decreased LN count after Pre-RT was related to good survival \[[@CR16], [@CR17]\]. The NLN count is particularly useful in the prediction of survival because it is little influenced by the number of LN retrieved, and has potential to reflect the dissection of lymphatic micrometastasis. In this study, we revealed that NLN count was an independent prognostic factor for patients with RC who received Pre-RT. Subgroup analysis showed that NLN was a prognosis factor for patients with RC who received Pre-RT in stage ypI (χ2 = 7.080; *P* = 0.008), ypII (χ2 = 20.806; *P* \< 0.001) and ypIII (χ2 = 33.138; *P* \< 0.001), respectively. It might provide more accurate prognostic information than the N stage alone in patients with Pre-RT.

This study has several limitations. First, the SEER database does not include information of therapeutic options such as detailed information of chemotherapy, targeted therapy, immunotherapy, recurrence and metastasis, which may also impact patients' prognosis. Second, this data lack detailed description of preoperative clinical grading and the information about tumor and LN recession response to treatment, and our analyses could not adjust for these potential confounding factor. Third, different operative approaches, doctors and even pathologist would affect the detective rate of total LN and metastatic LN, but the SEER do not include these information \[[@CR10]\]. Although future clinical research will be required to confirm the role of NLN, our study has its convincing power for it is one of the largest population based study until now.

Conclusions {#Sec11}
===========

Our results firmly demonstrated that NLN count was an independent prognostic factor for patients with RC who received Pre-RT. It could provide more accurate prognostic information for RC patients with Pre-RT (stage ypI, ypII and ypIII, respectively).
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